US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,374.50

+9.860.72%

Number of Gainers:15

Number of Losers:5

Number of Flat:- -

PE:- -

High:1,380.29

Open:1,364.76

Low:1,358.78

Close:1,364.65

Loading ...

Pfizer : Citigroup Raises Target Price to $25 From $23

THOMSON REUTERS

Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?

Pfizer : Leerink Partners Cuts Target Price to $26 From $28

THOMSON REUTERS

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

Flutter Entertainment plc (FLUT): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance

American Airlines Group Inc. (AAL): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

Moderna Inc. Publishes Document on mRNA-Encoded Masked IL-12 for Improved Systemic Tolerability and Anti-Tumor Efficacy

Late-Trading Activity (4 p.m. - 6 p.m. Eastern Time)

Health Care Climbs Amid Mixed Earnings - Health Care Roundup

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

MT Newswires Live

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

Astrazeneca Does not Expect Material Long-Term Impact From US Tariffs, CEO Says

MT Newswires Live

U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors

THOMSON REUTERS

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Simply Wall St.

Pfizer CEO: 'We should not have tariffs' on pharma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1374.5028,"timestamp":1746043199999,"preClose":1364.6454,"halted":0,"volume":107826428,"delay":0,"changeRate":0.007223,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":9.857422,"latestTime":"04-30 16:00:00 EDT","open":1364.7573,"high":1380.285,"low":1358.7754,"amount":5575004763.048491,"amplitude":0.015762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746057600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.640146,"peRate":22.008402,"turnoverRate":0.006953,"increases":15,"decrements":5,"flats":0,"marketCap":1135599575121,"floatMarketCap":1115674225455},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1380.285,"amplitude":0.015762,"preClose":1364.6454,"low":1358.7754,"pbRate":"3.640146","latestPrice":1374.5028,"volume":107826428,"delay":0,"open":1364.7573,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1344.1606,"twentyDayClose":1377.6108,"sixtyDayClose":1350.7439,"secType":"PLATE","market":"US","turnoverRate":0.006953,"peRate":22.008402,"marketCap":1135599575121,"floatMarketCap":1115674225455,"timestamp":1746043199999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":15,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531084287","title":"Pfizer : Citigroup Raises Target Price to $25 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2531084287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531084287?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:23","pubTimestamp":1746008602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BBT3K403.USD","IE00B19Z3581.USD","LU0225771236.USD","LU0321505439.SGD","SG9999002232.USD","BK4568","BK4581","BK4007","LU1894683264.USD","LU0122379950.USD","LU1883839398.USD","SG9999001176.USD","LU0306807586.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4534","BK4588","LU0234572021.USD","PFE","BK4550","LU0170899867.USD","SG9999003800.SGD","LU0058720904.USD","LU0289739699.SGD","SG9999013999.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","BK4585","SG9999011175.SGD","LU0306806265.USD","LU1066051498.USD","LU1894683348.USD","LU0321505868.SGD","LU0225284248.USD","LU1066053197.SGD","IE00BLSP4239.USD","IE0002270589.USD","SG9999002224.SGD","LU0868494617.USD","BK4599","LU0456855351.SGD","LU0985481810.HKD","LU1057294990.SGD","BK4533","IE00BLSP4452.SGD","BK4592"],"gpt_icon":0},{"id":"2531084511","title":"Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531084511","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531084511?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:15","pubTimestamp":1746008100,"startTime":"0","endTime":"0","summary":"A high dividend yield can be enticing, but it can also raise flags for income investors.Pfizer's falling valuation has pushed its yield up to well over 7%, which warrants a closer look.When a stock yields more than 5%, investors start to become skeptical about whether the payout is indeed safe. While it's tempting to want to believe that it can be safe and that it can be an excellent source of future dividend income, you also don't want to get burned and see that dividend get cut or suspended.Consider pharmaceutical giant Pfizer . Its dividend yield is around 7.5% right now, and if the stock continues to decline, it may not be long before it hits 8%. The big question is whether this is really a steal of a deal and a good buy, or if Pfizer may soon have to reduce its dividend?Pfizer's dividend looks safe right now, and with the stock trading at just 8 times its estimated future earnings, it could prove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/pfizers-dividend-yield-is-75-is-it-still-safe/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0225771236.USD","SG9999013999.USD","LU0170899867.USD","US2Y.BOND","LU1066051498.USD","LU0456855351.SGD","SG9999011175.SGD","BK4534","SG9999001176.USD","SG9999002232.USD","SG9999002224.SGD","LU1057294990.SGD","BK4588","US3Y.BOND","PFE","IE000M9KFDE8.USD","BK4007","BK4581","IE00BBT3K403.USD","LU0225284248.USD","US5Y.BOND","IE0002270589.USD","SG9999001176.SGD","US6M.BOND","LU0306806265.USD","LU1894683348.USD","LU0122379950.USD","BK4568","BK4533","BK4599","LU0234572021.USD","LU1066053197.SGD","US30Y.BOND","IE00BLSP4239.USD","LU0058720904.USD","LU0306807586.USD","LU1894683264.USD","SG9999003800.SGD","BK4592","LU1883839398.USD","BK4550","US12M.BOND","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0289739699.SGD","LU0985481810.HKD","US7Y.BOND","US10Y.BOND"],"gpt_icon":1},{"id":"2531081327","title":"Pfizer : Leerink Partners Cuts Target Price to $26 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2531081327","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531081327?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:04","pubTimestamp":1746007496,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683348.USD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU0306806265.USD","LU0321505439.SGD","LU1057294990.SGD","LU1066051498.USD","LU0225284248.USD","BK4599","LU0321505868.SGD","BK4568","LU1066053197.SGD","LU1894683264.USD","PFE","SG9999013999.USD","LU0170899867.USD","BK4581","IE00BBT3K403.USD","LU0122379950.USD","LU0234572021.USD","BK4550","BK4534","BK4592","SG9999002232.USD","LU0868494617.USD","LU1883839398.USD","BK4533","SG9999003800.SGD","LU0289739699.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0058720904.USD","BK4585","LU0306807586.USD","SG9999001176.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU1023059063.AUD","LU0225771236.USD","BK4007","BK4588","SG9999002224.SGD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2531024397","title":"Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531024397","media":"Motley Fool","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531024397?lang=en_us&edition=fundamental","pubTime":"2025-04-30 16:51","pubTimestamp":1746003060,"startTime":"0","endTime":"0","summary":"Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer.Pfizer should be able to easily fund an acquisition of either small drugmaker.However, Pfizer could hold off on the acquisitions front to see how its obesity drug PF-07976016 fares in clinical testing.The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs. Other drugmakers are eyeing the market as well.Pfizer  is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on experimental obesity pill danuglipron because of safety concerns. Could Pfizer solve the issue by acquiring an up-and-coming biotech with a promising obesity drug in clinical development?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/will-pfizer-will-acquire-altimmune-or-viking-thera/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0306807586.USD","BK4592","LU0058720904.USD","LU1894683348.USD","LU0122379950.USD","LU0234572021.USD","LU1066053197.SGD","LU1023059063.AUD","SG9999001176.SGD","SGXZ57979304.SGD","LU1066051498.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","SG9999013999.USD","LU0985481810.HKD","BK4139","LU0225771236.USD","BK4568","VKTX","PFE","BK4581","LU1057294990.SGD","IE0002270589.USD","SG9999001176.USD","BK4585","LU0170899867.USD","IE00BBT3K403.USD","LU1883839398.USD","IE00B19Z3581.USD","BK4007","LU0225284248.USD","LU0289739699.SGD","BK4588","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","IE00BLSP4239.USD","LU0321505868.SGD","SG9999003800.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999011175.SGD","BK4550","BK4533","LU1894683264.USD","IE000M9KFDE8.USD","BK4534","BK4599"],"gpt_icon":1},{"id":"2531945707","title":"Flutter Entertainment plc (FLUT): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2531945707","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531945707?lang=en_us&edition=fundamental","pubTime":"2025-04-30 15:48","pubTimestamp":1745999311,"startTime":"0","endTime":"0","summary":"We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where Flutter Entertainment plc  stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential.Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson’s Tiger Management. Robertson put together a formidable team of young traders – called the Tiger Cubs – in the 1990s, and most founded their own hedge funds after exit. Some other noteworthy names include Robert Citrone, Chase Coleman, and John Griffin. Halvorsen is the wealthiest Tiger Cub. Forbes Magazine ranks him at position 382 in the Richest People in the World in 2025 list with an $8 billion net worth.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/flutter-entertainment-plc-flut-among-074831124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4568","BK4535","LU0575583348.USD","LU1015430645.USD","BK4150","BK4551","BK4585","BNTX","BK4139","SGXZ81514606.USD","FLUT","SGXZ51526630.SGD","BK4588","SGXZ99366536.SGD"],"gpt_icon":0},{"id":"2531708938","title":"Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2531708938","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531708938?lang=en_us&edition=fundamental","pubTime":"2025-04-30 15:15","pubTimestamp":1745997300,"startTime":"0","endTime":"0","summary":"Both Pfizer and Viking aim to enter the high-growth weight loss drug market.Analysts forecast this market could be worth as much as $130 billion just a few years from now.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/prediction-pfizers-loss-may-be-viking-therapeutics/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0225771236.USD","IE00B19Z3581.USD","SG9999013999.USD","LU0170899867.USD","LU1066051498.USD","LU0456855351.SGD","SG9999011175.SGD","BK4534","SG9999001176.USD","SG9999002232.USD","VKTX","SG9999002224.SGD","LU1057294990.SGD","BK4588","LU1023059063.AUD","PFE","IE000M9KFDE8.USD","BK4007","BK4139","BK4581","IE00BBT3K403.USD","LU0225284248.USD","IE0002270589.USD","SG9999001176.SGD","LU0306806265.USD","LU1894683348.USD","LU0321505439.SGD","LU0122379950.USD","LU0321505868.SGD","BK4533","BK4568","BK4599","LU0234572021.USD","LU1066053197.SGD","IE00BLSP4239.USD","LU0058720904.USD","LU0306807586.USD","LU1894683264.USD","SG9999003800.SGD","BK4592","LU1883839398.USD","BK4585","BK4550","IE00BLSP4452.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0289739699.SGD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2531720867","title":"Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2531720867","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531720867?lang=en_us&edition=fundamental","pubTime":"2025-04-30 14:00","pubTimestamp":1745992800,"startTime":"0","endTime":"0","summary":"Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900  after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST. Nanobiotix will host an event on Monday, May 5th at 8:00AM EDT / 2:00PM CEST to review the presented results. PARIS andCAMBRIDGE, Mass., April 30, 2025  -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900  in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nanobiotix-announces-presentation-full-results-060000184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","LU1914381329.SGD","IE00B1BXHZ80.USD","LU1267930813.SGD","LU2112291526.USD","IE0009355771.USD","BK4585","BK4568","IE00BSNM7G36.USD","LU1244550577.SGD","LU1261432733.SGD","LU0345769631.USD","LU0345770308.USD","LU0098860793.USD","LU1732800096.USD","LU0985320562.USD","LU1032955483.USD","BK4504","LU0234572021.USD","LU1066053197.SGD","LU2347655156.SGD","LU2430703095.HKD","IE000M9KFDE8.USD","LU1280957306.USD","LU0466842654.USD","LU0203347892.USD","LU2468319806.SGD","LU1778281490.HKD","IE00BDGV0183.EUR","IE00B4R5TH58.HKD","LU1221951129.SGD","LU1196500208.SGD","LU1929549753.HKD","IE0034235303.USD","LU2430703251.USD","JNJ","LU0203345920.USD","LU2505996509.AUD","LU1894683348.USD","LU0795875169.SGD","LU2089984988.USD","LU1244550221.USD","LU2602419157.SGD","LU1162221912.USD","LU1023059063.AUD","LU0912757837.SGD","IE00BLSP4452.SGD","NBTX","IE00B3T34201.USD","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2531720386","title":"Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2531720386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531720386?lang=en_us&edition=fundamental","pubTime":"2025-04-30 12:38","pubTimestamp":1745987926,"startTime":"0","endTime":"0","summary":"Pfizer Inc ( ($PFE) ) has released its Q1 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors. Pfizer Inc., a le...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizer-reports-strong-q1-2025-results-and-reaffirms-guidance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizer-reports-strong-q1-2025-results-and-reaffirms-guidance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002270589.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU1883839398.USD","LU0058720904.USD","LU0868494617.USD","SG9999001176.USD","SG9999003800.SGD","SG9999011175.SGD","LU1023059063.AUD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","BK4007","LU0225771236.USD","LU0122379950.USD","LU1894683348.USD","BK4585","LU0170899867.USD","LU1066051498.USD","LU1057294990.SGD","BK4588","LU1066053197.SGD","PFE","BK4568","LU0985481810.HKD","SG9999001176.SGD","IE00BLSP4452.SGD","BK4592","LU0306807586.USD","SG9999002232.USD","LU0225284248.USD","BK4599","BK4533","LU0321505439.SGD","BK4550","LU0306806265.USD","IE00B19Z3581.USD","LU0321505868.SGD","LU0234572021.USD","BK4534","LU0456855351.SGD","SG9999013999.USD","SG9999002224.SGD","LU1894683264.USD","BK4581","IE000M9KFDE8.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2531992745","title":"American Airlines Group Inc. (AAL): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2531992745","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531992745?lang=en_us&edition=fundamental","pubTime":"2025-04-30 08:18","pubTimestamp":1745972331,"startTime":"0","endTime":"0","summary":"We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where American Airlines Group Inc.  stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential.Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson’s Tiger Management. Robertson put together a formidable team of young traders – called the Tiger Cubs – in the 1990s, and most founded their own hedge funds after exit. Some other noteworthy names include Robert Citrone, Chase Coleman, and John Griffin. Halvorsen is the wealthiest Tiger Cub. Forbes Magazine ranks him at position 382 in the Richest People in the World in 2025 list with an $8 billion net worth.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/american-airlines-group-inc-aal-001851292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTX","BK4568","USAW.SI","MNQmain","USJW.SI","BK4548",".IXIC","BK4547","NVIW.SI","NQmain","TSYW.SI","TQQQ","BK4008","BK4139","BK4551","BK4535","QID","BK4588","AAL","BK4585","BK4500","QLD","PSQ","SQQQ"],"gpt_icon":1},{"id":"2531482017","title":"Moderna Inc. Publishes Document on mRNA-Encoded Masked IL-12 for Improved Systemic Tolerability and Anti-Tumor Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531482017","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531482017?lang=en_us&edition=fundamental","pubTime":"2025-04-30 07:20","pubTimestamp":1745968815,"startTime":"0","endTime":"0","summary":"Moderna Inc. has published a document detailing a study on mRNA-encoded masked IL-12, showcasing its potential as a safe and effective immunotherapy. The study highlights the approach of using CytomX's PROBODY Therapeutics masking technology alongside Moderna's mRNA platform to improve systemic tolerability and maintain anti-tumor efficacy in preclinical models. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on April 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nNDL6T0zLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","BK4532","BK4585","BK4533","BK4588","CTMX","BK4568","BK4501","BK4551","BK4139","BK4548","BK4534"],"gpt_icon":0},{"id":"2531163716","title":"Late-Trading Activity (4 p.m. - 6 p.m. Eastern Time)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531163716","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531163716?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:18","pubTimestamp":1745965080,"startTime":"0","endTime":"0","summary":"ISSUE                   EXCH   VOL        LAST     NET CHG       % CHG. SPDR S&P 500                 4,227.0      553.79       —0.53        —0.1. SPDR Blm HY Bd               4,012.1       95.10       —0.17        —0.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4512","NC","BK4568","LU0306807586.USD","LU1894683264.USD","BK4508","NA","BK4534","BK4007","BK4610","IE00B19Z3581.USD","LU0058720904.USD","SBUX","SG9999001176.USD","BK4529","LU1057294990.SGD","SG9999003800.SGD","BK4599","LU0321505439.SGD","BK4576","BK4504","BK4551","IE00BLSP4239.USD","LU0122379950.USD","BK4543","LU1883839398.USD","IE00B3T34201.USD","LU0306806265.USD","BK4535","LU1066051498.USD","BK4550","BK4527","BK4579","IE0002270589.USD","BK4588","BK4209","LU2543165471.USD","EML","BK4592","LU0234572021.USD","BK4585","BK4605","LU0170899867.USD","LU0321505868.SGD","LU0456855351.SGD","LU0868494617.USD","BK4141"],"gpt_icon":1},{"id":"2531900657","title":"Health Care Climbs Amid Mixed Earnings - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2531900657","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531900657?lang=en_us&edition=fundamental","pubTime":"2025-04-30 05:06","pubTimestamp":1745960760,"startTime":"0","endTime":"0","summary":"Pfizer reaffirmed its outlook for the year, and announced another round of cost cuts as the beleaguered drugmaker looks to turn around its business postpandemic.Hims & Hers shares soared after it struck a deal with Danish obesity-drug maker Novo Nordisk to sell its popular Wegovy drug online. Shares of Novo Nordisk rose, but remain down by about 25% for the year to date.Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to invest in the U.S. as tariffs targeting the industry loom.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU1883839398.USD","LU0058720904.USD","LU0868494617.USD","SG9999001176.USD","SG9999003800.SGD","SG9999011175.SGD","LU1023059063.AUD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","BK4007","LU0225771236.USD","LU0122379950.USD","LU1894683348.USD","BK4585","LU0170899867.USD","LU1066051498.USD","LU1057294990.SGD","BK4588","LU1066053197.SGD","PFE","BK4568","LU0985481810.HKD","SG9999001176.SGD","IE00BLSP4452.SGD","BK4592","LU0306807586.USD","SG9999002232.USD","LU0225284248.USD","BK4599","BK4533","LU0321505439.SGD","BK4550","LU0306806265.USD","IE00B19Z3581.USD","LU0321505868.SGD","LU0234572021.USD","BK4534","LU0456855351.SGD","SG9999013999.USD","SG9999002224.SGD","LU1894683264.USD","BK4581","IE000M9KFDE8.USD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2531710023","title":"Gilead Sciences to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2531710023","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531710023?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957100,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., April 29, 2025----Gilead Sciences, Inc.  announced today that its executives will be speaking at the following investor conferences:. BofA Securities Health Care Conference on Tuesday, May 13 at 11:20 AM Pacific Time. RBC Capital Markets Global Healthcare Conference on Wednesday, May 21 at 11:30 AM Eastern Time. Bernstein Annual Strategic Decisions Conference on Thursday, May 29 at 2:30 PM Eastern Time. Jefferies Global Healthcare Conference on Wednesday, June 4 at 11:05 AM Eastern Time. Goldman Sachs Annual Global Healthcare Conference on Tuesday, June 10 at 11:20 AM Eastern Time. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-present-upcoming-investor-200500133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4583","BK4585","LU0889565916.HKD","LU1839511570.USD","LU0320765992.SGD","GILD","LU0109394709.USD","BK4568","IE00B3T34201.USD","LU1430594728.SGD","LU1571399168.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0234570918.USD","BK4532","IE00BKVL7J92.USD","LU1066053197.SGD","LU2468319806.SGD","BK4578","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4550","LU2087621335.USD","LU2089984988.USD","BK4588","BK4139","LU1066051498.USD","LU1585245621.USD","BK4566"],"gpt_icon":0},{"id":"2531767764","title":"Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2531767764","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531767764?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:19","pubTimestamp":1745950748,"startTime":"0","endTime":"0","summary":"Gilead Sciences  has agreed to pay $202 million in the settlement of a civil fraud lawsuit accusing it of paying kickbacks to healthcare practitioners to promote its HIV treatment drugs, the US Attorney for the Southern District of New York said in a Tuesday statement.The illegal kickbacks caused false claims for Gilead's HIV drugs to be paid by federal healthcare programs, in violation of the False Claims Act, according to the statement.Under the settlement, Gilead agreed to pay a total sum of $202 million, of which around $176.9 million will be paid to the US and the remainder will be paid to various states.  As part of the settlement, the company also made extensive factual admissions regarding its conduct, the statement said.The settlement was approved Monday by US District Judge Paul Engelmayer.Gilead did not immediately reply to a request for comment from MT Newswires.Price: 106.17, Change: -0.17, Percent Change: -0.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z3B42.SGD","LU0058720904.USD","LU0889565916.HKD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU2087621335.USD","BK4585","LU0320765992.SGD","BK4578","GILD","BK4588","LU1585245621.USD","BK4566","LU1571399168.USD","BK4139","LU2089984988.USD","IE0002270589.USD","BK4532","LU0234570918.USD","BK4568","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU1839511570.USD","LU1066053197.SGD","LU1430594728.SGD","BK4550","IE00BZ1G4Q59.USD","LU1066051498.USD","IE00B3T34201.USD","IE00BKVL7J92.USD","LU0289739699.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2531679957","title":"Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2531679957","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531679957?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:11","pubTimestamp":1745950260,"startTime":"0","endTime":"0","summary":"Stock market investors have been punishing Pfizer's stock. Given the stock's generous 7% yield, maybe junk bond investors should take a look.The venerable drug company, which also developed one of the first Covid-19 vaccines, has seen its share price languish lately. The stock, which peaked at nearly $60 in 2022, has since seen its market value halved -- thanks to coming patent expirations and worries the Trump administration's tariffs could hurt sector profits.On Tuesday, Pfizer reported better-than-expected earnings, but missed Wall Street revenue forecasts. Shares rose about 4% to $24 during the session.The big decline in Pfizer's share price may have a silver lining. The stock now yields 7.4%, according to Morningstar. That's high enough to compete with junk bonds: The iShares iBoxx $ High Yield Corporate Bond ETF, a popular exchange-traded fund, yields 7.5%.And junk bonds could see significant price declines if the economy weakens further and investors begin to seriously worry abo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU1023059063.AUD","BK4585","BK4534","LU1057294990.SGD","SG9999002224.SGD","US5Y.BOND","BK4007","LU0058720904.USD","US2Y.BOND","BK4581","LU0868494617.USD","SG9999011175.SGD","BK4568","HYG","LU1066051498.USD","LU0456855351.SGD","BK4533","US30Y.BOND","SG9999003800.SGD","US3Y.BOND","US10Y.BOND","BK4599","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","BK4550","US6M.BOND","BK4592","SG9999013999.USD","SG9999001176.SGD","LU0289739699.SGD","LU1894683264.USD","LU0170899867.USD","US7Y.BOND","LU1066053197.SGD","US12M.BOND","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0225284248.USD","PFE","BK4588","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2531576750","title":"Astrazeneca Does not Expect Material Long-Term Impact From US Tariffs, CEO Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2531576750","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531576750?lang=en_us&edition=fundamental","pubTime":"2025-04-30 02:04","pubTimestamp":1745949869,"startTime":"0","endTime":"0","summary":"Astrazeneca  does not expect material long-term impact from the potential US tariffs on import of medicines from Europe to the US, the company's chief executive officer Pascal Soriot said in Q1 earnings call Tuesday.Soriot said the company has 11 manufacturing sites in the US, and majority of its medicines sold in the US are made domestically. In addition, the company is making mitigating efforts for the minority of medicines it imports from Europe for sale in the US.Due to ongoing inventory management, the company expects to remain within its full-year 2025 guidance range provided the tariffs are implemented in line with other sectors.\"We now have 31 manufacturing sites globally, and we also supply for the vast majority of our medicines. Our supply chains for China and the US are largely segregated and we have very limited commercialized finished medicines imported from the US to China, meaning that our exposure to the current China tariffs on pharmaceuticals is not material in the co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2236285917.USD","LU0889565916.HKD","LU0109394709.USD","LU2456880835.USD","BK4588","AZN","LU2462157665.USD","BK4568","LU2417539215.USD","BK4007","BK4585","LU1829250122.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2531764556","title":"U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764556?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0234570918.USD","LU2089984988.USD","LU0320765992.SGD","BK4532","LU0289739699.SGD","GILD","BK4583","LU1430594728.SGD","BK4568","LU0109394709.USD","LU1839511570.USD","LU1066051498.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","IE0002270589.USD","IE00B3T34201.USD","IE00B7SZLL34.SGD","BK4578","LU1585245621.USD","BK4588","BK4566","IE00BSNM7G36.USD","LU1066053197.SGD","LU0889565916.HKD","LU1571399168.USD","IE00B19Z3581.USD","BK4139","BK4585","IE00BKVL7J92.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","BK4550"],"gpt_icon":0},{"id":"2531764206","title":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764206","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764206?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctorsNEW YORK, April 29 (Reuters) - Gilead Sciences GILD.O has reached a $202 million settlement to resolve a civil fraud la","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0234570918.USD","LU1066051498.USD","LU2089984988.USD","BK4532","LU1839511570.USD","LU2087621335.USD","LU0058720904.USD","IE00B19Z3B42.SGD","IE0002270589.USD","LU1571399168.USD","LU1066053197.SGD","IE00B19Z3581.USD","BK4550","BK4583","IE00BKVL7J92.USD","LU0109394709.USD","LU0889565916.HKD","LU1585245621.USD","BK4578","LU1430594728.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","BK4566","IE00B3T34201.USD","BK4585","GILD","LU0320765992.SGD","BK4588","BK4568","LU2468319806.SGD"],"gpt_icon":0},{"id":"2531789793","title":"Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789793","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789793?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:27","pubTimestamp":1745947636,"startTime":"0","endTime":"0","summary":"Gilead Sciences recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results where a significant net income turnaround was noted. These developments, combined with a quarterly dividend declaration and ongoing share buybacks, potentially supported a 13% share price increase over the last quarter. Meanwhile, the general market showed strength with a 7% rise, suggesting Gilead's performance aligns with broader positive trends, further buoyed by robust earnings reports across various industries.We've identified 2 possible red flags with Gilead Sciences and understanding the impact should be part of your investment process.NasdaqGS:GILD Revenue & Expenses Breakdown as at Apr 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-showcases-172716096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","LU1571399168.USD","LU2087621335.USD","BK4585","LU1585245621.USD","BK4578","IE00B19Z3581.USD","LU0289739699.SGD","IE0002270589.USD","LU0058720904.USD","LU0234570918.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","GILD","BK4532","LU2089984988.USD","LU0109394709.USD","LU0889565916.HKD","BK4139","IE00B7SZLL34.SGD","BK4583","LU1430594728.SGD","LU1066051498.USD","BK4568","LU1066053197.SGD","LU1839511570.USD","BK4588","LU0320765992.SGD","LU2468319806.SGD","IE00BKVL7J92.USD","BK4550","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2531761289","title":"Pfizer CEO: 'We should not have tariffs' on pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2531761289","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531761289?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:16","pubTimestamp":1745947001,"startTime":"0","endTime":"0","summary":"Like his Big Pharma peers, Pfizer  CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure, he said Tuesday, the government's national security concerns are \"legitimate.\" But, he added, \"we should not have tariffs.\". \"No country wants to have critical medicines produced ... in countries where tensions are high or can escalate,\" Bourla said on an earnings call. He did not detail what percent of manufacturing is taking place and which components are being produced in the US, but said the company has contingency plans in place.\"If there are tariffs, we have detailed contingency plans that are minimizing the impact. But I'm right now focusing more on the fact that we should not have tariffs,\" Bourla said.CFO David Denton said the company is already expecting a $150 million impact in 2025 from the current slate of tariffs but did not detail which products are impacted.Read more about Pfizer's stock mo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-ceo-we-should-not-have-tariffs-on-pharma-171641146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999001176.USD","LU0868494617.USD","LU0985481810.HKD","LU0234572021.USD","IE00BLSP4239.USD","BK4592","SG9999011175.SGD","LU1066051498.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU1066053197.SGD","BK4568","LU0456855351.SGD","BK4550","BK4533","LU0306807586.USD","LU0889565916.HKD","LU0170899867.USD","BK4581","BK4585","BK4588","BK4007","LU0225771236.USD","LU1023059063.AUD","BK4534","LU0320765992.SGD","LU2417539215.USD","SGXZ57979304.SGD","AZN","LU2236285917.USD","LU0225284248.USD","LU1883839398.USD","SG9999013999.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","PFE","IE00BLSP4452.SGD","SG9999003800.SGD","LU0109394709.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","SG9999002232.USD","LU1894683264.USD","LU1829250122.USD","LU2462157665.USD","LU0058720904.USD","IE0002270589.USD","LU0321505439.SGD","SG9999002224.SGD","LU0289739699.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":16,"pageCount":2,"totalSize":304,"code":"91000000","status":"200"}]}}